Dr. Reddy’s Laboratories (NYSE:RDY) announces the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of AstraZeneca’s (NYSE:AZN) FDA approved Faslodex (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL).
Per IQVIA, the U.S. market is ~$407M.
https://seekingalpha.com/news/3611953-dr-reddys-launches-generic-faslodex-injection-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.